Antiemetics: American Society of Clinical Oncology clinical practice guideline update
PJ Hesketh, MG Kris, E Basch, K Bohlke… - Journal of Clinical …, 2017 - ascopubs.org
Purpose To update the ASCO guideline for antiemetics in oncology. Methods ASCO
convened an Expert Panel and conducted a systematic review of the medical literature for …
convened an Expert Panel and conducted a systematic review of the medical literature for …
2016 MASCC and ESMO guideline update for the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting and of nausea and vomiting in …
F Roila, A Molassiotis, J Herrstedt, M Aapro… - Annals of …, 2016 - annalsofoncology.org
Despite the considerable progress achieved in the last 30 years, vomiting and, especially,
nausea, continue to be two of the most distressing side-effects of cancer chemotherapy. In …
nausea, continue to be two of the most distressing side-effects of cancer chemotherapy. In …
Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta‐analysis
V Piechotta, A Adams, M Haque… - Cochrane Database …, 2021 - cochranelibrary.com
Background About 70% to 80% of adults with cancer experience chemotherapy‐induced
nausea and vomiting (CINV). CINV remains one of the most distressing symptoms …
nausea and vomiting (CINV). CINV remains one of the most distressing symptoms …
[HTML][HTML] Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology …
K Aogi, H Takeuchi, T Saeki, K Aiba, K Tamura… - International Journal of …, 2021 - Springer
Patients with cancer should appropriately receive antiemetic therapies against
chemotherapy-induced nausea and vomiting (CINV). Antiemetic guidelines play an …
chemotherapy-induced nausea and vomiting (CINV). Antiemetic guidelines play an …
[HTML][HTML] 2023 MASCC and ESMO guideline update for the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting
J Herrstedt, R Clark-Snow, CH Ruhlmann… - ESMO open, 2024 - Elsevier
Nausea and vomiting are still considered to be two of the most troublesome adverse events
(AEs) for patients treated with antineoplastic therapy. To optimise the utility of available …
(AEs) for patients treated with antineoplastic therapy. To optimise the utility of available …
Projecting individualized absolute invasive breast cancer risk in US Hispanic women
MP Banegas, EM John, ML Slattery… - Journal of the …, 2017 - academic.oup.com
Background: The NEDD8 conjugation pathway modulates the ubiquitination and activity of a
wide range of intracellular proteins, and its blockade by pevonedistat is emerging as a …
wide range of intracellular proteins, and its blockade by pevonedistat is emerging as a …
MiR‐34b/c‐5p and the neurokinin‐1 receptor regulate breast cancer cell proliferation and apoptosis
L Zhang, L Wang, D Dong, Z Wang, W Ji, M Yu… - Cell …, 2019 - Wiley Online Library
Objectives MiR‐34 is a tumour suppressor in breast cancer. Neurokinin‐1 receptor (NK1R),
which is the predicted target of the miR‐34 family, is overexpressed in many cancers. This …
which is the predicted target of the miR‐34 family, is overexpressed in many cancers. This …
2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following moderately emetogenic chemotherapy
F Roila, D Warr, PJ Hesketh, R Gralla… - Supportive Care in …, 2017 - Springer
Purpose An update of the recommendations for the prophylaxis of acute and delayed
emesis induced by moderately emetogenic chemotherapy published after the last …
emesis induced by moderately emetogenic chemotherapy published after the last …
Effect of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in women: a randomized clinical trial
Importance The prevention of chemotherapy-induced nausea and vomiting has an important
role in the overall management of cancer treatment. Objective To evaluate whether adding …
role in the overall management of cancer treatment. Objective To evaluate whether adding …
Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting
RM Navari, LS Schwartzberg - OncoTargets and therapy, 2018 - Taylor & Francis
To examine pharmacologic and clinical characteristics of neurokinin 1 (NK1)-receptor
antagonists (RAs) for preventing chemotherapy-induced nausea and vomiting (CINV) …
antagonists (RAs) for preventing chemotherapy-induced nausea and vomiting (CINV) …